$15.80
4.43% today
Nasdaq, Feb 28, 04:50 pm CET
ISIN
IE00B91XRN20
Symbol
PRTA
Sector
Industry

Prothena Corp. Plc Stock price

$15.13
-0.91 5.67% 1M
-6.24 29.20% 6M
+1.28 9.24% YTD
-15.17 50.07% 1Y
-19.47 56.27% 3Y
+4.32 39.96% 5Y
-11.45 43.08% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
+0.58 3.99%
ISIN
IE00B91XRN20
Symbol
PRTA
Sector
Industry

Key metrics

Market capitalization $814.13m
Enterprise Value $353.58m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 2.62
P/S ratio (TTM) P/S ratio 6.02
P/B ratio (TTM) P/B ratio 1.67
Revenue growth (TTM) Revenue growth 47.92%
Revenue (TTM) Revenue $135.16m
EBIT (operating result TTM) EBIT $-154.56m
Cash position $471.39m
EPS (TTM) EPS $-2.30
P/E forward negative
P/S forward 16.09
EV/Sales forward 6.99
Short interest 26.45%
Show more

Is Prothena Corp. Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Prothena Corp. Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Prothena Corp. Plc forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Prothena Corp. Plc forecast:

Buy
80%
Hold
20%

Financial data from Prothena Corp. Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
135 135
48% 48%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 65 65
200% 200%
48%
- Research and Development Expense 223 223
1% 1%
165%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -155 -155
19% 19%
-114%
Net Profit -122 -122
17% 17%
-90%

In millions USD.

Don't miss a Thing! We will send you all news about Prothena Corp. Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Prothena Corp. Plc Stock News

Neutral
Seeking Alpha
8 days ago
Prothena Corporation plc (NASDAQ:PRTA ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Mark Johnson - Vice President of Investor Relations Gene Kinney - President and Chief Executive Officer Chad Swanson - Chief Development Officer Tran Nguyen - Chief Financial Officer and Chief Strategy Officer Brandon Smith - Chief Operating Officer Conference Call Particip...
Neutral
Business Wire
8 days ago
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena reported financial results for the 4th quarter and full year 2024. The Company also provided business highlights and 2025 financial guidance.
Neutral
GlobeNewsWire
11 days ago
NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Prothena Corporation PLC (NASDAQ: PRTA) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
More Prothena Corp. Plc News

Company Profile

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Gene Kinney
Founded 1969
Website www.prothena.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today